Who are CDFR0613's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brenzavvy, Jardiance, Bexagliflozin tablets, Insulin/Empaglifozin, Concomitant therapy 14 days, Dapagliflozin + Lobeglitazone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cdfr0613.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CDFR0613 — Competitive Intelligence Brief

CDFR0613 (CDFR0613) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CDFR0613 (CDFR0613) — CTC Bio, Inc.. CDFR0613 is a small molecule that targets the SGLT2 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CDFR0613 TARGET	CDFR0613	CTC Bio, Inc.	phase 3	SGLT2 inhibitor	SGLT2
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	marketed	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
Bexagliflozin tablets	Bexagliflozin tablets	Theracos	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Insulin/Empaglifozin	Insulin/Empaglifozin	University of Campania Luigi Vanvitelli	marketed	Insulin + SGLT2 inhibitor combination	Insulin receptor; SGLT2 (sodium-glucose cotransporter 2)
Concomitant therapy 14 days	Concomitant therapy 14 days	Incheon St.Mary's Hospital	marketed	SGLT2 inhibitor	SGLT2
Dapagliflozin + Lobeglitazone	Dapagliflozin + Lobeglitazone	Seoul National University Bundang Hospital	marketed	SGLT2 inhibitor + thiazolidinedione combination	SGLT2 and PPAR-γ

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CDFR0613 — Competitive Intelligence Brief. https://druglandscape.com/ci/cdfr0613. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab